Biocon enters pact with Mexican firm to market generic human insulin in US
1 min read . Updated: 17 Mar 2016, 07:29 PM ISTBiocon entered into a co-development and commercialization agreement with PiSA for generic recombinant human insulin for the US market
Hyderabad: Biopharmaceutical firm Biocon Ltd on Thursday said it has entered into a co-development and commercialization agreement with Mexican drug maker Laboratorios PiSA S.A. de C.V (PiSA) for generic recombinant human insulin (rh-insulin) for the US market.
This is a cost and profit sharing agreement, with Biocon being responsible for clinical development, regulatory approvals and commercialisation of the product in the US, the company said in a statement to stock exchanges.
The drug substance will be made by Biocon, while the drug product will be made by PiSA at its Mexico facility.
Shares of Biocon gained 0.21% and were trading at ₹ 474.90 at 9.22 am on BSE, while the benchmark Sensex index rose 1.04% and was trading at 24,940.29 points.
Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.
